Second Booster BNT162b2 Restores SARS-CoV-2 Humoral Response in Patients With Multiple Myeloma, Excluding Those Under Anti-BCMA Therapy
Ioannis Ntanasis‐Stathopoulos(National and Kapodistrian University of Athens), Evangelos Terpos(National and Kapodistrian University of Athens), Μαρία Ρούσσου(National and Kapodistrian University of Athens), Evangelos Eleutherakis‐Papaiakovou(National and Kapodistrian University of Athens), Meletios Α. Dimopoulos(National and Kapodistrian University of Athens), Ioannis P. Trougakos(National and Kapodistrian University of Athens), Harry Alexopoulos(National and Kapodistrian University of Athens), Panagiotis Malandrakis(National and Kapodistrian University of Athens), Foteini Theodorakakou(National and Kapodistrian University of Athens), Aimilia D. Sklirou(National and Kapodistrian University of Athens), Magdalini Migkou(National and Kapodistrian University of Athens), Maria Gavriatopoulou(National and Kapodistrian University of Athens), Despina Fotiou(National and Kapodistrian University of Athens), Vangelis Karalis(National and Kapodistrian University of Athens), Vassiliki A. Iconomidou(National and Kapodistrian University of Athens), Efstathios Kastritis(AOL (United States))
Cited by 44
Related Papers
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Hematological findings and complications of <scp>COVID</scp>‐19
|American Journal of Hematology|2020|1.7k